Barclay Pearce Capital | Research

27 October 2020



Russell Wright | T+02 8288 6900 | E:russell@barclaypearce.com.AU

Resources and Energy Group Limited (REZ)


Diversified Metals and Mining - Gold SPECULATIVE BUY

REZ A\$0.096 **TARGET PRICE** A\$0.15

Resources & Energy Group Limited explores for, develops, and produces gold and silver deposits in AUstralia. Its flagship project is the Menzies project that consists of 50 tenements covering an area of 103 square kilometres located in the north of Kalgoorlie, Western AUstralia. The company was incorporated in 2004 and is based in Sydney, AUstralia.

Company Data

Number of shares (M)	387.7
Market Capitalisation	\$40.7M
Free float (%)	N/A
12-month high/low	\$0.11/\$0.01
Average Daily Turnover (\$m)	0.0354
% S&P/ASX200	0.00%
DDM Ranking	N/A
% All Ordinaries	0.00%
GICS Industry Group Source: FactSet, Barclay Pearce Capital	Materials



Source: Barclay Pearce Capital



High Grade find at Gigante Grande-66m thick zone from 71m with a peak result of 1m @ 76.4g/t AU.

On 20 October 2020 Resources & Energy Group Limited (REZ) announced the discovery of a new high-grade zone of gold mineralisation at Gigante Grande Prospect situated in the 100% owned East Menzies Gold Field Project with the following highlights:

- The initial RC drilling campaign designed to drill test the previously reported 2.5km by 400m AU in regolith gold anomalies, has been completed;
- Results for only five holes of the initial 32-hole drill program have been received and significant intervals of gold mineralisation have been found in two of them; 20EMRC012 and 20EMRC002;
- A peak assay of 1m @ 76.4g/t AU from 134m down the hole has been intersected in 20EMRC012 within a 66m mineralised zone from 71 to 137m down the hole and 20m @ 5.06g/t AU from 116m;
- Mineralisation within 20EMRC012 is not isolated to the high-grade zones, with a continuum of lower tenor results, ranging from 0.1 to 0.6g/t AU occurring throughout;
- When combined with 20EMRAB44 (34m@0.29g/t AU), the thickness of the mineralised package is approximately 100m;
- 20EMRC002, located 490m north-northwest of 20EMRC012, and has intersected a 19m thick gold mineralised interval from 34 to 52m down the hole, with a peak assay of 1m@13g/t AU from 35m, which includes 8m@3.02g/t from 35m;
- This interval is within a broader 24m thick zone of gold mineralisation, from 31m to 55m down the hole, with results ranging from 0.1 to 1.15g/t AU throughout;
- There is potential for this zone continuing further north along the east side of the Project Area, which is bounded by the Moriarty Shear Zone;
- These drilling results give added weight to the prospect that Gigante Grande hosts a very large mineralised gold system; and
- The discovery of high-grade gold mineralisation, below the regolith in the Gigante Grande area, has potential to lead to a new economic gold deposit which is less than 130km North of Kalgoorlie, and more specifically, within the eastern part of the historic Menzies Goldfield.

The Executive Director of REZ Mr Richard Poole commented: "This is an amazing initial drill result @ 76.4g/t AU from our first follow up of RC holes at Gigante Grande. The results support the overwhelming evidence that the East Menzies Gold Field is one of Australia's best and most overlooked exploration target areas. Given its huge historical yield and rich history of gold production and discoveries, with over 400 old workings we are very excited. We are very much looking forward to continuing to explore and develop our 100sqkm containing multiple Prospects at the East Menzies Gold Field."

Investment summary

The Gigante Grande is one of a number of prospects acquired by REZ in late 2018 through its acquisition of Menzies Goldfield Limited, operator of the East Menzies Gold Project. The RC program was designed to drill deeper into the fresh bedrock to test potential for higher grade mineralised systems.

Additional assays are expected over the next 2 weeks. We anticipate that these will continue to deliver strong results at Gigante Grande quickly building on historical resources.

This gives us confidence to initiate on REZ with a 12-month price target of \$0.15 and a SPECULATIVE BUY recommendation.



Russell Wright | T+02 8288 6900 | E:russell@barclaypearce.com.AU

27 October 2020

This Research Report has been prepared by Russell Wright ("Mr Wright") in his capacity as a Corporate Authorised Representative (CAR: 422117) and issued (in Australia) by Barclay Pearce Capital Pty Ltd (ACN 634 843 735) (AFS Licence No. 503 261) ("Barclay Pearce Capital") and remains the property of Barclay Pearce Capital Pty Ltd. No material contained in this Research may be reproduced or distributed, except as allowed by the Copyright Act, without the prior written approval of Barclay Pearce Capital. This Research Report is subject to the disclosures and restrictions set out below.

Analyst Certification

The research analyst(s) identified on the cover of this report individually certify that in respect of each security or issuer that the research analyst covers that: this report accurately reflects his or her personal views about any and all of the subject issuer(s) or securities; and no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or views expressed by the research analyst(s) in this report.

Barclay Pearce Capital provides research services to its client. Mr Wright is General Manager of Research and has over twenty (30) years' experience in the financial services industry, particularly in financial analysis and research report writing. Mr Wright joined the Barclay Pearce team in 2020 where he has been involved in the research and publication of reports. Prior to this Mr Wright worked at a number of entities where he held Director/Head of Research and General Manager of Research positions. Mr Wright holds a Bachelor of Mathematics (Honours) from Edinburgh University and has completed the SDIA Accreditation Program (RG146) through DeakinPrime.

General Disclosure

Barclay Pearce Capital and its associates (as defined in Chapter 1 of the Corporations Act 2001), officers, directors, employees and agents, from time to time, may own or have positions in securities of the company(ies) covered in this report and may trade in the securities mentioned either as principal or agent or may be materially interested in such securities.

Barclay Pearce Capital does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Barclay Pearce Capital provides research on all ASX200 stocks as well as on other sectors (i.e. artificial intelligence, crypto currencies, food, healthcare, marijuana, mining, payment platforms and technologies) and/or entities which Barclay Pearce Capital considers to be of interest to both Barclay Pearce Capital's clients and the broader financial markets.

Disclaimer & Warning

This report may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This report does not purport to contain all the information that a prospective investor may require. Before making an investment or trading decision, the recipient must consider market developments subsequent to the date of this document, and whether the advice is appropriate in light of his or her financial circumstances or seek further advice on its appropriateness or should form his/her own independent view given the person's investment objectives, financial situation and particular needs regarding any securities or Financial Products mentioned herein. Information in this document has been obtained from sources believed to be true but neither Barclay Pearce Capital nor its associates make any recommendation or warranty concerning the Financial Products or the accuracy, or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. This document is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any Financial Product, and neither this document or anything in it shall form the basis of any contract or commitment. Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Barclay Pearce Capital, its associates, officers, directors, employees and agents. The securities of such company(ies) may not be eligible for sale in all jurisdictions or to all categories of investors.

Analysts' Compensation: The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of the analyst(s) research, client evaluation feedback, independent survey rankings and overall firm revenues, which include revenues from, among other business units and corporate finance.

Other International Investors: International investors outside the US, UK, UAE or Canada are encouraged to contact their local regulatory AUthorities to determine whether any restrictions apply to their ability to purchase this investment and should seek their own advice

Recipient Representations/Warranties: By accepting this report, the recipient represents and warrants that he or she is entitled to receive such report in accordance with the restrictions set out in this document and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of law.

Meanings of Barclay Pearce Capital Stock Ratings

Buy – Describes stocks that we expect to provide a total return (price appreciation plus net yield) of 15% or more within a 12-month period. **Hold** – Describes stocks that are neither a buy nor underperform.

Underperform – Describes stocks that we expect to provide a total return (price appreciation plus net yield) of less than minus 10% within a 12-month period.

NR – The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Barclay Pearce Capital policies.

Speculative Buy – Describes stocks we research with a positive bias, whose company fundamentals and/or financials are being covered, but for which there is insufficient information for Barclay Pearce Capital to assign a Buy or Underperform rating.

Barclay Pearce Capital | Research



27 October 2020

Russell Wright | T+02 8288 6900 | E:russell@barclaypearce.com.AU

Free Float (float / current shares outstanding) *100 – This float figure is the number of shares that are available to the public and is calculated by subtracting the shares held by insiders and those deemed to be stagnant shareholders. Stagnant holders include ESOP's, ESOT's, QUEST's, employee benefit trusts, founding shareholder equity stake plus senior management equity stake, corporations not actively managing money, venture capital companies and shares held by Governments.

Valuation Methodology

Barclay Pearce Capital's methodology for assigning stock and credit ratings may include the following: market capitalisation, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of peer comparisons, market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of parts, net asset value, discounted dividend model (DDM), franking credits and return on equity (ROE) over the next 12 months.

Conflicts of Interest

Barclay Pearce Capital does not have any material interests in the financial product discussed in this Research Report nor will it receive any benefits in relation to the publication of this Research Report. Barclay Pearce Capital manages all Conflicts of Interest in accordance with its Conflicts of Interest Policy. Please contact us if you require any further information.